The Medical Research Council trial of misonidazole in carcinoma of the uterine cervix. A report from the MRC Working Party on misonidazole for cancer of the cervix.
153 patients from 13 centres were entered into a randomised controlled trial of the hypoxic cell sensitiser , misonidazole, in the radiotherapy of Stage III carcinoma of the uterine cervix. In an interim analysis at a time when follow-up periods extended from 9 to 45 months, no benefit in survival or local tumour control has been demonstrated. When disease-free survival of all cases was considered it was found that the younger patients did less well than the older patients and that the greater the immediate response to radiotherapy the longer was the duration of survival free of disease.
D000328:Adult; D000368:Aged; D001918:Brachytherapy; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D008920:Misonidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D009593:Nitroimidazoles / Q000627:therapeutic use*; D011379:Prognosis; D011832:Radiation Injuries; D011879:Radiotherapy Dosage; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000532:radiotherapy*
D009593:Nitroimidazoles; D008920:Misonidazole